IL2 and neoplasm: Our prior work had shown that intratumoral (IT) treatment delivered more anti-GD2 agent to the tumor than IV treatment [29], and that IT hu14.18-IL2 immunocytokine (IC) induced a more potent immunotherapeutic effect than the same dose of IV hu14.18-IL2.